Oculis Holding AG
Private Company
Total funding raised: $124M
Overview
Oculis is a clinical-stage biotech on a mission to save sight and improve eye care through visionary innovation in topical drug delivery. The company has built a highly differentiated late-stage pipeline anchored by three core assets: OCS-01 for DME, Licaminlimab for dry eye disease, and Privosegtor for neuro-ophthalmic conditions like optic neuritis. Its strategy leverages proprietary technology platforms to address vast unmet medical needs in ophthalmology, transitioning key programs into Phase 3 trials following a successful U.S. IPO in 2023 which provided capital to advance its ambitious clinical agenda.
Technology Platform
OPTIREACH® solubilizing nanoparticle technology for topical delivery to the back of the eye, and a proprietary neuroprotective peptoid platform (Privosegtor) designed to cross the blood-brain and blood-retinal barriers.
Pipeline
9| Drug | Indication | Stage | Watch |
|---|---|---|---|
| OCS-01 + Vehicle | Inflammation Eye Pain | Phase 3 | |
| Dexamethasone Ophthalmic Suspension | Inflammation Eye | Phase 3 | |
| Dexamethasone ophthalmic suspension (OCS-01) + Vehicle | Diabetic Macular Edema | Phase 3 | |
| Dexamethasone ophthalmic suspension (OCS-01) + Vehicle | Diabetic Macular Edema | Phase 2/3 | |
| OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic ... | Inflammation Corneal | Phase 2 |
Funding History
3
Company Timeline
Founded in Lausanne, Switzerland
Series A: $32.0M
Series B: $57.0M
IPO — $35.0M